FDA-cleared profile

Rapid CTA 360

iSchemaView · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.

Clinical role
Parallel radiological triage and notification to surface suspected vessel occlusion for clinician attention; it does not alter the original study or provide a diagnosis.
Images and patients
CT/CTA · Brain
Key limitation
Keep in mind: The software is for triage and notification, not diagnosis or primary image interpretation. Notifications are informational, can be delayed or absent, and require review of the original CTA by qualified clinicians. The validated sensitivity and specificity apply to the FDA-described adult datasets and vessel definitions.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain Input: Adult head CTA DICOM examinations covering the specified intracranial and vertebral vessel segments.
  • Who uses it?Intended users: Trained clinicians and stroke teams who review head CTA triage notifications and the source examination; a notification does not replace professional judgment or diagnosis.
  • What does the software produce?Output: Suspected occlusion triage notifications, reports, and DICOM Secondary Capture or compressed preview content for clinician workflow; the original CT study is not changed.
  • What is its most important limitation?Key limitation: The software is for triage and notification, not diagnosis or primary image interpretation. Notifications are informational, can be delayed or absent, and require review of the original CTA by qualified clinicians. The validated sensitivity and specificity apply to the FDA-described adult datasets and vessel definitions.

Clinical takeaway. Clinical role: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.

Evidence takeaway. Evidence from the reviewed source record: K251151 FDA evidence is a regulatory head-CTA triage and notification validation; no independent paper or trial was promoted in this timeboxed review.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Parallel radiological triage and notification to surface suspected vessel occlusion for clinician attention; it does not alter the original study or provide a diagnosis.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
Adult head CTA DICOM examinations covering the specified intracranial and vertebral vessel segments.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
Suspected occlusion triage notifications, reports, and DICOM Secondary Capture or compressed preview content for clinician workflow; the original CT study is not changed.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Emergency, stroke, radiology, or neurovascular workflow in which adult head CTA is acquired and urgent triage notification is needed.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Trained clinicians and stroke teams who review head CTA triage notifications and the source examination; a notification does not replace professional judgment or diagnosis.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
The software is for triage and notification, not diagnosis or primary image interpretation. Notifications are informational, can be delayed or absent, and require review of the original CTA by qualified clinicians. The validated sensitivity and specificity apply to the FDA-described adult datasets and vessel definitions.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
K251151 FDA evidence is a regulatory head-CTA triage and notification validation; no independent paper or trial was promoted in this timeboxed review.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K251151 FDA evidence is a regulatory head-CTA triage and notification validation; no independent paper or trial was promoted in this timeboxed review.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
92.1% (95% CI: 88.0%, 94.9%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
89% (95% CI: 83.2%, 92.9%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Occlusion sensitivity

0.921 proportion

  • EndpointSensitivity for the FDA-defined suspected occlusion endpoint
  • Population403 independent adult head CTA examinations with three-expert reference review
  • Tested versionRapid CTA 360 configuration described in K251151

Occlusion specificity

0.89 proportion

  • EndpointSpecificity for the FDA-defined suspected occlusion endpoint
  • Population403 independent adult head CTA examinations with three-expert reference review
  • Tested versionRapid CTA 360 configuration described in K251151

Median time to notification

3.2 minutes

  • EndpointTime from study availability to triage notification
  • PopulationFDA validation notification cases
  • Tested versionRapid CTA 360 configuration described in K251151

HGS sensitivity

0.874 proportion

  • EndpointSensitivity for the FDA-defined high-grade stenosis/occlusion subgroup
  • PopulationIndependent adult head CTA validation cases
  • Tested versionRapid CTA 360 configuration described in K251151

K251151 Rapid CTA 360 regulatory validation

  • DesignRetrospective regulatory development, test, and independent validation of computer-aided head-CTA triage and notification against three-expert reference review.
  • PopulationDevelopment/test corpus of 6,264 cases from 133 sites; final independent validation of 403 adult CTA examinations across scanner vendors with three-expert 2-of-3 reference review.
  • Scopeexact submission
  • Tested versionRapid CTA 360 configuration described in K251151
  • Samplen=403
  • Sites133
  • IndependenceSponsor or vendor study

K251151

Manufacturer-submitted FDA evidence; the 403-case test set is independent of development but the overall evidence is regulatory, not an independent clinical-outcome study.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The wave22 exact-submission recall query returned no native recall record for K251151. This does not establish absence of family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-07
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult head CTA DICOM examinations covering the specified intracranial and vertebral vessel segments.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K251151: Rapid CTA 360

  2. Routing

    Source context, not route validation: The exact system receives adult head CTA DICOM studies, processes them in parallel with standard reading, and sends notifications and DICOM Secondary Capture or preview outputs; local PACS/RIS routing, notification channels, downtime, and escalation require acceptance testing.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K251151: Rapid CTA 360

  3. AI processing

    Source context, not route validation: The FDA packet describes server or standalone desktop deployment with workflow notifications; the reviewed exact materials do not establish current hosting topology, service availability, retention, or infrastructure terms for a particular installation.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 · FDA 510(k) K251151: Rapid CTA 360

  4. Returned objects

    Source context, not route validation: Suspected occlusion triage notifications, reports, and DICOM Secondary Capture or compressed preview content for clinician workflow; the original CT study is not changed.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K251151: Rapid CTA 360

  5. Viewer/worklist/report

    Unresolved route: Suspected occlusion triage notifications, reports, and DICOM Secondary Capture or compressed preview content for clinician workflow; the original CT study is not changed.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K251151: Rapid CTA 360

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA packet describes server or standalone desktop deployment with workflow notifications; the reviewed exact materials do not establish current hosting topology, service availability, retention, or infrastructure terms for a particular installation.
  • Exact FDA submission
  • Checked 2026-09-07
Integration
The exact system receives adult head CTA DICOM studies, processes them in parallel with standard reading, and sends notifications and DICOM Secondary Capture or preview outputs; local PACS/RIS routing, notification channels, downtime, and escalation require acceptance testing.
  • Exact FDA submission
  • Checked 2026-09-07
Security
The FDA packet describes an OWASP risk process, annual ISO 27001/27701 certification, and UL-2900-1 conformance as part of the reviewed security evidence; current certificate scope, expiry, deployed configuration, and operational controls require confirmation.
  • Exact FDA submission
  • Checked 2026-09-07

This records the exact FDA packet's described evidence and is not a current independent security attestation.

Training
Trained clinicians must review notifications against the original CTA and understand that the output is triage-only; local onboarding should cover covered vessel segments, notification failure and delay, escalation, and downtime procedures.
  • Exact FDA submission
  • Checked 2026-09-07
Monitoring
Monitor CTA eligibility, notification latency and delivery, false-positive and false-negative review, original-study review completion, DICOM routing, downtime and escalation, software updates, complaints, and recalls by exact K251151 release.
  • Exact FDA submission
  • Checked 2026-09-07

Buyer acceptance guidance derived from the exact FDA workflow and validation scope; it is not a claimed vendor monitoring service.

Parallel CTA triage workflow

The exact submission processes head CTA in parallel with standard reading and sends workflow notifications while leaving the original study unchanged; test notification latency, delivery, escalation, and downtime locally.

exact submission · checked 2026-09-07

Rapid CTA family stroke workflow

RapidAI describes Rapid CTA as automatically processing CTA to assess reduced blood flow, identify and locate suspected large- or distal-vessel occlusion, and notify stroke teams for transfer decisions.

product family · checked 2026-09-07

Current family workflow page; it does not establish every feature, vessel scope, or deployment term for the K251151 release.

DICOM notification and preview outputs

The FDA packet describes DICOM Secondary Capture and compressed preview or notification outputs; establish local PACS storage, mobile/web or other notification channels, retention, and clinician acknowledgement procedures.

exact submission · checked 2026-09-07
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K251151
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-07-16
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
26Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The stored PubMed and ClinicalTrials.gov candidate arrays were screened and were empty. No paper or trial was promoted; empty stored arrays do not establish that no external literature or trials exist. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, fda device recall, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-07 - Exact FDA submission

    No public list price or contract unit for the exact K251151 configuration was established in the reviewed official sources.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Rapid CTA 360 RapidAI reimbursement CPT NTAP"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. RapidAI's reimbursement page lists NTAP for Rapid LVO (FY2021-2022 rules); it does not name this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

8 sources - 3 history items

Source ledger

  1. FDA 510(k) K251151: Rapid CTA 360

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: identity, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, integration, deployment, security, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Rapid CTA 360 model card (K251151)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. RapidAI stroke transfer decisions: Rapid CTA

    RapidAI / iSchemaView - Accessed 2026-09-07

    Scope: productFamily, clinicalUse, implementationCapabilities

  8. openFDA exact recall query for K251151

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: postmarketSafety

Research history

  1. K251151 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251590

Methinks CTA Stroke

Methinks Software S.L.

Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-08-20
FDA-cleared K250685

Methinks NCCT Stroke

Methinks Software S.L.

Authorized purpose: Methinks NCCT Stroke analyzes adult non-contrast head CT to flag suspected intracranial hemorrhage and suspected large-vessel occlusion of the ICA, MCA-M1, or MCA-M2 for parallel workflow triage via PACS and/or notifications; previews are informational, not diagnostic, and a negative notification does not rule out LVO or replace CTA/standard care.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-06-16
FDA-cleared K243294

Brainomix 360 e-ASPECTS

Brainomix Limited

Authorized purpose: Brainomix 360 e-ASPECTS registers adult non-contrast brain CT, segments ASPECTS regions, and provides an editable ASPECTS score with highlighted regions and voxel contribution views to assist trained clinicians evaluating suspected ischemic stroke within 24 hours of last known well.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-02-14

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history